Proactive Investors’ Andrew Scott sits down with Arix Bioscience Plc’s (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma to discuss the Series B financing.
Artios in strong position to accelerate cancer programmes after Arix investment
| Media coverage